© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 12, 1017-1024,
June 16, 1999
© 1999 Oxford University Press
Cancer Surveillance Series: Interpreting Trends in Prostate Cancer—Part I: Evidence of the Effects of Screening in Recent Prostate Cancer Incidence, Mortality, and Survival Rates
Affiliations of authors: B. F. Hankey, E. J. Feuer, L. X. Clegg, J. M. Legler, L. A. Ries (Division of Cancer Control and Population Sciences), R. B. Hayes (Division of Cancer Epidemiology and Genetics), P. C. Prorok (Division of Cancer Prevention), R. S. Kaplan (Division of Cancer Treatment), National Cancer Institute, Bethesda, MD; R. M. Merrill, Health Sciences Department, Brigham Young University, Provo, UT.
Correspondence to: Benjamin F. Hankey, Sc.D., National Institutes of Health, Executive Plaza North, Rm. 343J, Bethesda, MD 20892 (e-mail: bh43a{at} nih.gov).
BACKGROUND: The prostate-specific antigen test was approved by the U.S. Food and Drug Administration in 1986 to monitor the disease status in patients with prostate cancer and, in 1994, to aid in prostate cancer detection. However, after 1986, the test was performed on many men who had not been previously diagnosed with prostate cancer, apparently resulting in the diagnosis of a substantial number of early tumors. Our purpose is to provide insight into the effect of screening on prostate cancer rates. Detailed data are presented for whites because the size of the population allows for calculating statistically reliable rates; however, similar overall trends are seen for African-Americans and other races. METHODS: Prostate cancer incidence data from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program and mortality data from the National Center for Health Statistics were analyzed. RESULTS/CONCLUSIONS: The following findings are consistent with a screening effect: 1) the recent decrease since 1991 in the incidence of distant stage disease, after not having been perturbed by screening; 2) the decline in the incidence of earlier stage disease beginning the following year (i.e., 1992); 3) the recent increases and decreases in prostate cancer incidence and mortality by age that appear to indicate a calendar period effect; and 4) trends in the incidence of distant stage disease by tumor grade and trends in the survival of patients with distant stage disease by calendar year that provide suggestive evidence of the tendency of screening to detect slower growing tumors. IMPLICATIONS: The decline in the incidence of distant stage disease holds the promise that testing for prostate-specific antigen may lead to a sustained decline in prostate cancer mortality. However, population data are complex, and it is difficult to confidently attribute relatively small changes in mortality to any one cause.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. M. Hillier, K. P. Maresca, F. J. Femia, J. C. Marquis, C. A. Foss, N. Nguyen, C. N. Zimmerman, J. A. Barrett, W. C. Eckelman, M. G. Pomper, et al. Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer Cancer Res., September 1, 2009; 69(17): 6932 - 6940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Richiardi, V. Fiano, L. Vizzini, L. De Marco, L. Delsedime, O. Akre, A. G. Tos, and F. Merletti Promoter Methylation in APC, RUNX3, and GSTP1 and Mortality in Prostate Cancer Patients J. Clin. Oncol., July 1, 2009; 27(19): 3161 - 3168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Pashayan, P. Pharoah, D. E Neal, F. Hamdy, J. Donovan, R. M Martin, D. Greenberg, and S. W Duffy Stage shift in PSA-detected prostate cancers - effect modification by Gleason score J Med Screen, June 1, 2009; 16(2): 98 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Roddam, N. E. Allen, P. Appleby, T. J. Key, L. Ferrucci, H. B. Carter, E. J. Metter, C. Chen, N. S. Weiss, A. Fitzpatrick, et al. Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies Ann Intern Med, October 7, 2008; 149(7): 461 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zuccolo, R. Harris, D. Gunnell, S. Oliver, J. A. Lane, M. Davis, J. Donovan, D. Neal, F. Hamdy, R. Beynon, et al. Height and Prostate Cancer Risk: A Large Nested Case-Control Study (ProtecT) and Meta-analysis Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2325 - 2336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cosetti, G.-P. Yu, and S. P. Schantz Five-Year Survival Rates and Time Trends of Laryngeal Cancer in the US Population Arch Otolaryngol Head Neck Surg, April 1, 2008; 134(4): 370 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Hormones and Prostate Cancer Collaborative Group Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies J Natl Cancer Inst, February 6, 2008; 100(3): 170 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. McLerran, W. E. Grizzle, Z. Feng, I. M. Thompson, W. L. Bigbee, L. H. Cazares, D. W. Chan, J. Dahlgren, J. Diaz, J. Kagan, et al. SELDI-TOF MS Whole Serum Proteomic Profiling with IMAC Surface Does Not Reliably Detect Prostate Cancer Clin. Chem., January 1, 2008; 54(1): 53 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H Patel and D. R Kockler Sipuleucel-T: A Vaccine for Metastatic, Asymptomatic, Androgen-Independent Prostate Cancer Ann. Pharmacother., January 1, 2008; 42(1): 91 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kvale, A. Auvinen, H.-O. Adami, A. Klint, E. Hernes, B. Moller, E. Pukkala, H. H. Storm, L. Tryggvadottir, S. Tretli, et al. Interpreting Trends in Prostate Cancer Incidence and Mortality in the Five Nordic Countries J Natl Cancer Inst, December 19, 2007; 99(24): 1881 - 1887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. R. Farwell, J. A. Linder, and A. K. Jha Trends in Prostate-Specific Antigen Testing From 1995 Through 2004 Arch Intern Med, December 10, 2007; 167(22): 2497 - 2502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Otto, F. H. Schroder, and H. J. de Koning Risk of Cardiovascular Mortality in Prostate Cancer Patients in the Rotterdam Randomized Screening Trial J. Clin. Oncol., September 1, 2006; 24(25): 4184 - 4189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Oberaigner, W. Horninger, H. Klocker, D. Schonitzer, W. Stuhlinger, and G. Bartsch Reduction of Prostate Cancer Mortality in Tyrol, Austria, after Introduction of Prostate-specific Antigen Testing Am. J. Epidemiol., August 15, 2006; 164(4): 376 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Parker, L. Cohen, V. A. Bhadkamkar, R. J. Babaian, M. A. Smith, E. R. Gritz, and K. M. Basen-Engquist Demographic and Past Screening Behaviors of Men Attending a Free Community Screening Program for Prostate Cancer Health Promot Pract, April 1, 2006; 7(2): 213 - 220. [Abstract] [PDF]
|
|
|
|
|
|
P. C. Albertsen, J. A. Hanley, G. H. Barrows, D. F. Penson, P. D. H. Kowalczyk, M. M. Sanders, and J. Fine Prostate Cancer and the Will Rogers Phenomenon J Natl Cancer Inst, September 7, 2005; 97(17): 1248 - 1253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Routh and B. C. Leibovich Adenocarcinoma of the Prostate: Epidemiological Trends, Screening, Diagnosis, and Surgical Management of Localized Disease Mayo Clin. Proc., July 1, 2005; 80(7): 899 - 907. [Abstract] [PDF]
|
|
|
|
|
|
E. A. Platz, M. F. Leitzmann, N. Rifai, P. W. Kantoff, Y.-C. Chen, M. J. Stampfer, W. C. Willett, and E. Giovannucci Sex Steroid Hormones and the Androgen Receptor Gene CAG Repeat and Subsequent Risk of Prostate Cancer in the Prostate-Specific Antigen Era Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1262 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bosetti, M. Malvezzi, L. Chatenoud, E. Negri, F. Levi, and C. La Vecchia Trends in cancer mortality in the Americas, 1970-2000 Ann. Onc., March 1, 2005; 16(3): 489 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Brenner and V. Arndt Long-Term Survival Rates of Patients With Prostate Cancer in the Prostate-Specific Antigen Screening Era: Population-Based Estimates for the Year 2000 by Period Analysis J. Clin. Oncol., January 20, 2005; 23(3): 441 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Wilding and P. Remington Period Analysis of Prostate Cancer Survival J. Clin. Oncol., January 20, 2005; 23(3): 407 - 409. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Shaw, R. Etzioni, S. B. Zeliadt, A. Mariotto, K. Karnofski, D. F. Penson, N. S. Weiss, and E. J. Feuer An Ecologic Study of Prostate-specific Antigen Screening and Prostate Cancer Mortality in Nine Geographic Areas of the United States Am. J. Epidemiol., December 1, 2004; 160(11): 1059 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. McNaughton-Collins, E. Walker-Corkery, and M. J. Barry Health-Related Quality of Life, Satisfaction, and Economic Outcome Measures in Studies of Prostate Cancer Screening and Treatment, 1990-2000 J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 78 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tsujimoto, Y. Tomita, Y. Hoshida, T. Kono, T. Oka, S. Yamamoto, N. Nonomura, A. Okuyama, and K. Aozasa Elevated Expression of Valosin-Containing Protein (p97) Is Associated with Poor Prognosis of Prostate Cancer Clin. Cancer Res., May 1, 2004; 10(9): 3007 - 3012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. O. Freytag, H. Stricker, J. Pegg, D. Paielli, D. G. Pradhan, J. Peabody, M. DePeralta-Venturina, X. Xia, S. Brown, M. Lu, et al. Phase I Study of Replication-Competent Adenovirus-Mediated Double-Suicide Gene Therapy in Combination with Conventional-Dose Three-Dimensional Conformal Radiation Therapy for the Treatment of Newly Diagnosed, Intermediate- to High-Risk Prostate Cancer Cancer Res., November 1, 2003; 63(21): 7497 - 7506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Weir, M. J. Thun, B. F. Hankey, L. A. G. Ries, H. L. Howe, P. A. Wingo, A. Jemal, E. Ward, R. N. Anderson, and B. K. Edwards Annual Report to the Nation on the Status of Cancer, 1975-2000, Featuring the Uses of Surveillance Data for Cancer Prevention and Control J Natl Cancer Inst, September 3, 2003; 95(17): 1276 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. G. Nelson, A. M. De Marzo, and W. B. Isaacs Prostate Cancer N. Engl. J. Med., July 24, 2003; 349(4): 366 - 381. [Full Text] [PDF]
|
|
|
|
|
|
G. Draisma, R. Boer, S. J. Otto, I. W. van der Cruijsen, R. A. M. Damhuis, F. H. Schroder, and H. J. de Koning Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst, June 18, 2003; 95(12): 868 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Sirovich, L. M. Schwartz, and S. Woloshin Screening Men for Prostate and Colorectal Cancer in the United States: Does Practice Reflect the Evidence? JAMA, March 19, 2003; 289(11): 1414 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Chen, B. A. Miller, E. Giovannucci, and R. B. Hayes Height and the Survival of Prostate Cancer Patients Cancer Epidemiol. Biomarkers Prev., March 1, 2003; 12(3): 215 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kakehi Watchful Waiting as a Treatment Option for Localized Prostate Cancer in the PSA Era Jpn. J. Clin. Oncol., January 1, 2003; 33(1): 1 - 5. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jemal, T. Murray, A. Samuels, A. Ghafoor, E. Ward, and M. J. Thun Cancer Statistics, 2003 CA Cancer J Clin, January 1, 2003; 53(1): 5 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Bach, M. J. Kelley, R. C. Tate, and D. C. McCrory Screening for Lung Cancer: A Review of the Current Literature Chest, January 1, 2003; 123 (2009): 72S - 82S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Harris and K. N. Lohr Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, December 3, 2002; 137(11): 917 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lu-Yao, P. C Albertsen, J. L Stanford, T. A Stukel, E. S Walker-Corkery, and M. J Barry Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut BMJ, October 5, 2002; 325(7367): 740 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. X. Clegg, F. P. Li, B. F. Hankey, K. Chu, and B. K. Edwards Cancer Survival Among US Whites and Minorities: A SEER (Surveillance, Epidemiology, and End Results) Program Population-Based Study Arch Intern Med, September 23, 2002; 162(17): 1985 - 1993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Xu, D. A. Meyers, D. A. Sterling, S. L. Zheng, W. J. Catalona, S. D. Cramer, E. R. Bleecker, and J. Ohar Association Studies of Serum Prostate-specific Antigen Levels and the Genetic Polymorphisms at the Androgen Receptor and Prostate-specific Antigen Genes Cancer Epidemiol. Biomarkers Prev., July 1, 2002; 11(7): 664 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Gelmann Molecular Biology of the Androgen Receptor J. Clin. Oncol., July 1, 2002; 20(13): 3001 - 3015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. D. Andersen, P. Remington, A. Trentham-Dietz, and M. Reeves Assessing a Decade of Progress in Cancer Control Oncologist, June 1, 2002; 7(3): 200 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Gelmann, D. J. Steadman, J. Ma, N. Ahronovitz, H. J. Voeller, S. Swope, M. Abbaszadegan, K. M. Brown, K. Strand, R. B. Hayes, et al. Occurrence of NKX3.1 C154T Polymorphism in Men with and without Prostate Cancer and Studies of Its Effect on Protein Function Cancer Res., May 1, 2002; 62(9): 2654 - 2659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Perron, L. Moore, I. Bairati, P.-M. Bernard, and F. Meyer PSA screening and prostate cancer mortality Can. Med. Assoc. J., March 1, 2002; 166(5): 586 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Schantz and G.-P. Yu Head and Neck Cancer Incidence Trends in Young Americans, 1973-1997, With a Special Analysis for Tongue Cancer Arch Otolaryngol Head Neck Surg, March 1, 2002; 128(3): 268 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jemal, A. Thomas, T. Murray, and M. Thun Cancer Statistics, 2002 CA Cancer J Clin, January 1, 2002; 52(1): 23 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. I. Quinn, S. M. Henshall, A.-M. Haynes, P. C. Brenner, R. Kooner, D. Golovsky, J. Mathews, G. F. O'Neill, J. J. Turner, W. Delprado, et al. Prognostic Significance of Pathologic Features in Localized Prostate Cancer Treated With Radical Prostatectomy: Implications for Staging Systems and Predictive Models J. Clin. Oncol., August 15, 2001; 19(16): 3692 - 3705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Howe, P. A. Wingo, M. J. Thun, L. A. G. Ries, H. M. Rosenberg, E. G. Feigal, and B. K. Edwards Annual Report to the Nation on the Status of Cancer (1973 Through 1998), Featuring Cancers With Recent Increasing Trends J Natl Cancer Inst, June 6, 2001; 93(11): 824 - 842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Liu, W. Cozen, L. Bernstein, R. K. Ross, and D. Deapen Changing Relationship Between Socioeconomic Status and Prostate Cancer Incidence J Natl Cancer Inst, May 2, 2001; 93(9): 705 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Moller Trends in incidence of testicular cancer and prostate cancer in Denmark Hum. Reprod., May 1, 2001; 16(5): 1007 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Hoffman, F. D. Gilliland, J. W. Eley, L. C. Harlan, R. A. Stephenson, J. L. Stanford, P. C. Albertson, A. S. Hamilton, W. C. Hunt, and A. L. Potosky Racial and Ethnic Differences in Advanced-Stage Prostate Cancer: the Prostate Cancer Outcomes Study J Natl Cancer Inst, March 7, 2001; 93(5): 388 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Alers, P.-J. Krijtenburg, A. N. Vis, R. F. Hoedemaeker, M. F. Wildhagen, W. C. J. Hop, T. H. van der Kwast, F. H. Schroder, H. J. Tanke, and H. van Dekken Molecular Cytogenetic Analysis of Prostatic Adenocarcinomas from Screening Studies : Early Cancers May Contain Aggressive Genetic Features Am. J. Pathol., February 1, 2001; 158(2): 399 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pollack, G. K. Zagars, L. G. Smith, J. J. Lee, A. C. von Eschenbach, J. A. Antolak, G. Starkschall, and I. Rosen Preliminary Results of a Randomized Radiotherapy Dose-Escalation Study Comparing 70 Gy With 78 Gy for Prostate Cancer J. Clin. Oncol., December 1, 2000; 18(23): 3904 - 3911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. F. Hankey, L. A. Ries, and B. K. Edwards The Surveillance, Epidemiology, and End Results Program: A National Resource Cancer Epidemiol. Biomarkers Prev., December 1, 1999; 8(12): 1117 - 1121. [Full Text]
|
|
|
|
|
|
E. J. Feuer, R. M. Merrill, and B. F. Hankey Cancer Surveillance Series: Interpreting Trends in Prostate Cancer—Part II: Cause of Death Misclassification and the Recent Rise and Fall in Prostate Cancer Mortality J Natl Cancer Inst, June 16, 1999; 91(12): 1025 - 1032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Etzioni, J. M. Legler, E. J. Feuer, R. M. Merrill, K. A. Cronin, and B. F. Hankey Cancer Surveillance Series: Interpreting Trends in Prostate Cancer—Part III: Quantifying the Link Between Population Prostate-Specific Antigen Testing and Recent Declines in Prostate Cancer Mortality J Natl Cancer Inst, June 16, 1999; 91(12): 1033 - 1039. [Abstract] [Full Text] [PDF]
|
|